RedHill Biopharma Ltd.
RDHL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $2,039 | $2,039 | $2,736 | $2,736 |
| % Growth | 0% | -25.4% | 0% | – |
| Cost of Goods Sold | $804 | $804 | $894 | $894 |
| Gross Profit | $1,236 | $1,236 | $1,842 | $1,842 |
| % Margin | 60.6% | 60.6% | 67.3% | 67.3% |
| R&D Expenses | $482 | $482 | $465 | $465 |
| G&A Expenses | $1,926 | $1,926 | $2,049 | $2,049 |
| SG&A Expenses | $2,943 | $2,943 | $3,280 | $3,280 |
| Sales & Mktg Exp. | $1,018 | $1,018 | $1,232 | $1,232 |
| Other Operating Expenses | $0 | $0 | $1,180 | $1,180 |
| Operating Expenses | $3,425 | $3,425 | $4,924 | $4,924 |
| Operating Income | -$2,189 | -$2,189 | -$3,083 | -$3,083 |
| % Margin | -107.3% | -107.3% | -112.7% | -112.7% |
| Other Income/Exp. Net | $123 | $123 | $493 | $493 |
| Pre-Tax Income | -$2,067 | -$2,067 | -$2,590 | -$2,590 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,067 | -$2,067 | -$2,590 | -$2,590 |
| % Margin | -101.3% | -101.3% | -94.7% | -94.7% |
| EPS | -1 | -1 | -1 | -1 |
| % Growth | 0% | 0% | 0% | – |
| EPS Diluted | -1 | -1 | -1 | -1 |
| Weighted Avg Shares Out | 1,803 | 1,803 | 2,577 | 2,577 |
| Weighted Avg Shares Out Dil | 1,803 | 1,803 | 2,577 | 2,577 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $913 | $913 |
| Interest Expense | $512 | $512 | $0 | $0 |
| Depreciation & Amortization | $84 | $84 | $25 | $86 |
| EBITDA | -$2,105 | -$2,105 | -$1,879 | -$1,817 |
| % Margin | -103.2% | -103.2% | -68.7% | -66.4% |